Addition of @entity136 at the time of XXXX resistance in metastatic @entity1358 .

@entity1 @entity417 @entity2240 @entity882 @entity5 @entity1151 @entity1358 @entity1398 @entity136
OBJECTIVE:    To investigate the role of adding @entity136 at the time of @entity2240 failure in @entity1 with metastatic @entity1358 (mRCC). @entity1 AND METHODS:    A retrospective chart review of 13 @entity1 with mRCC who experienced disease progression on @entity2240 and received @entity136 750 mg/m(2) i.v. on days 1 and 8 and @entity2240 37.5 mg/day on days 2-15 every 21 days from September 2006-2009 was carried out.    Responses were assessed using the Response Evaluation Criteria in @entity5 .    The median age was 59, male to female ratio 10:3, Eastern Cooperative Oncology Group performance status 1-3; the number of prior regimens ranged from one to five, and duration on @entity2240 alone ranged from 3 months to >1 year. RESULTS:    Twelve out of 13 @entity1 received more than two cycles with one documented partial response, five stable disease and seven progressive disease.    The median time to progression was 21 weeks.    We documented grade 4 @entity1151 (n= 1), grade 3 @entity1398 (n= 2), @entity417 (n= 2) and @entity882 (n= 1). CONCLUSION:    The combination of @entity2240 and @entity136 in @entity1 with mRCC may delay disease progression in some @entity1 exhibiting resistance to @entity2240 . This regimen merits further prospective investigation in this @entity1 population.
